284 related articles for article (PubMed ID: 29737593)
1. Management of cancer-associated thrombosis in patients with thrombocytopenia: guidance from the SSC of the ISTH.
Samuelson Bannow BT; Lee A; Khorana AA; Zwicker JI; Noble S; Ay C; Carrier M
J Thromb Haemost; 2018 Jun; 16(6):1246-1249. PubMed ID: 29737593
[No Abstract] [Full Text] [Related]
2. Cancer-associated thrombosis: the when, how and why.
Fernandes CJ; Morinaga LTK; Alves JL; Castro MA; Calderaro D; Jardim CVP; Souza R
Eur Respir Rev; 2019 Mar; 28(151):. PubMed ID: 30918022
[TBL] [Abstract][Full Text] [Related]
3. [Thrombosis and cancer. An update of our knowledge].
Tumori; 2006; 92(5):23-41. PubMed ID: 17168451
[No Abstract] [Full Text] [Related]
4. Managing the competing risks of thrombosis, bleeding, and anticoagulation in patients with malignancy.
Al-Samkari H; Connors JM
Blood Adv; 2019 Nov; 3(22):3770-3779. PubMed ID: 31770442
[TBL] [Abstract][Full Text] [Related]
5. Rethinking the approach to thrombosis in patients with cancer.
Khorana AA
Vasc Med; 2020 Jun; 25(3):208-209. PubMed ID: 31718489
[No Abstract] [Full Text] [Related]
6. Anticoagulation of cancer patients with non-valvular atrial fibrillation receiving chemotherapy: Guidance from the SSC of the ISTH.
Delluc A; Wang TF; Yap ES; Ay C; Schaefer J; Carrier M; Noble S
J Thromb Haemost; 2019 Aug; 17(8):1247-1252. PubMed ID: 31207027
[No Abstract] [Full Text] [Related]
7. Peri-procedure management of antithrombotic agents and thrombocytopenia for common procedures in oncology: Guidance from the SSC of the ISTH.
Wang TF; Sanfilippo KM; Douketis J; Falanga A; Karageorgiou J; Maraveyas A; Ortel TL; Soff G; Vedantham S; Zwicker JI
J Thromb Haemost; 2022 Dec; 20(12):3026-3038. PubMed ID: 36217296
[TBL] [Abstract][Full Text] [Related]
8. Coagulation and cancer: biological and clinical aspects.
Falanga A; Marchetti M; Vignoli A
J Thromb Haemost; 2013 Feb; 11(2):223-33. PubMed ID: 23279708
[TBL] [Abstract][Full Text] [Related]
9. Heparin-induced thrombocytopenia and thrombosis syndrome after cardiopulmonary bypass.
Holmes-Ghosh E
Am J Crit Care; 2000 Jul; 9(4):276-8. PubMed ID: 10888150
[No Abstract] [Full Text] [Related]
10. Treatment and prevention of heparin-induced thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
Linkins LA; Dans AL; Moores LK; Bona R; Davidson BL; Schulman S; Crowther M
Chest; 2012 Feb; 141(2 Suppl):e495S-e530S. PubMed ID: 22315270
[TBL] [Abstract][Full Text] [Related]
11. The risk of major bleeding in patients with suspected heparin-induced thrombocytopenia.
Pishko AM; Lefler DS; Gimotty P; Paydary K; Fardin S; Arepally GM; Crowther M; Rice L; Vega R; Cines DB; Guevara JP; Cuker A
J Thromb Haemost; 2019 Nov; 17(11):1956-1965. PubMed ID: 31350937
[TBL] [Abstract][Full Text] [Related]
12. Heparin-induced thrombocytopenia: what clinicians need to know.
Chong BH; Isaacs A
Thromb Haemost; 2009 Feb; 101(2):279-83. PubMed ID: 19190810
[No Abstract] [Full Text] [Related]
13. Prevention of venous thromboembolism in cancer outpatients: guidance from the SSC of the ISTH.
Khorana AA; Otten HM; Zwicker JI; Connolly GC; Bancel DF; Pabinger I;
J Thromb Haemost; 2014 Nov; 12(11):1928-31. PubMed ID: 25208230
[No Abstract] [Full Text] [Related]
14. Heparin induced thrombocytopenia diagnosis in cardiac surgery: is there a role for thromboelastography?
Kouerinis IA; Kourtesis A; El-Ali M; Sergentanis T; Plagou A; Argiriou M; Theakos N; Giannakopoulou A
Interact Cardiovasc Thorac Surg; 2008 Aug; 7(4):560-3. PubMed ID: 18056152
[TBL] [Abstract][Full Text] [Related]
15. The serological profile of early-onset and persisting post-cardiac surgery thrombocytopenia complicated by "true" heparin-induced thrombocytopenia.
Warkentin TE; Moore JC; Vogel S; Sheppard JA; Warkentin NI; Eikelboom JW
Thromb Haemost; 2012 May; 107(5):998-1000. PubMed ID: 22371139
[No Abstract] [Full Text] [Related]
16. Heparin-induced thrombocytopenia and thrombosis syndrome after cardiac surgery.
DuBose J; Sutherland M; Moulton M; Krishnan B; Cohn J; Pratt JW
Curr Surg; 2004; 61(2):209-12. PubMed ID: 15051266
[TBL] [Abstract][Full Text] [Related]
17. Fondaparinux versus direct thrombin inhibitor therapy for the management of heparin-induced thrombocytopenia (HIT)--bridging the River Coumarin.
Warkentin TE
Thromb Haemost; 2008 Jan; 99(1):2-3. PubMed ID: 18217128
[No Abstract] [Full Text] [Related]
18. The identification of at-risk patients and prevention of venous thromboembolism in pediatric cancer: guidance from the SSC of the ISTH.
Tullius BP; Athale U; van Ommen CH; Chan AKC; Palumbo JS; Balagtas JMS;
J Thromb Haemost; 2018 Jan; 16(1):175-180. PubMed ID: 29178421
[No Abstract] [Full Text] [Related]
19. Risk factors for major bleeding in patients with heparin-induced thrombocytopenia treated with argatroban: a retrospective study.
Hursting MJ; Verme-Gibboney CN
J Cardiovasc Pharmacol; 2008 Dec; 52(6):561-6. PubMed ID: 19057393
[TBL] [Abstract][Full Text] [Related]
20. Management of challenging cases of patients with cancer-associated thrombosis including recurrent thrombosis and bleeding: guidance from the SSC of the ISTH.
Carrier M; Khorana AA; Zwicker J; Noble S; Lee AY;
J Thromb Haemost; 2013 Sep; 11(9):1760-5. PubMed ID: 23809334
[No Abstract] [Full Text] [Related]
[Next] [New Search]
